Manufacturing Chemist Stand Side with Piramal Pharma Solutions

Published: 17-Nov-2023 Featured companies: Piramal Pharma Solutions
Manufacturing

Having recently completed a successful rights issue related to the India stock market, Peter DeYoung, Piramal Pharma Ltd's CEO talks about the company's new and improved management programme, patient centricity and more

At this year's CPHI Barcelona, Manufacturing Chemist Stand Side caught up with Peter to discuss pharmaceutical market trends, such as the effects of the Inflation Reduction Act on the industry and reshoring, both in North America and India. 

He also provided updates on PPS’s Lexington sterile fill finish site, its integration with the Riverview API facility and the new plant's role in the company's ADCelerate programme (an integrated offering with the Grangemouth site providing rapid INDs for ADCs).

And, addressing complex lyophilised formulations, he also talked about API expansions at PPS sites worldwide and the global market demand for API/HPAPIs.
 

Manufacturing Chemist Stand Side...

'Manufacturing Chemist Stand Side' is a series of exclusive video interviews with leading companies in the pharmaceutical industry, conducted during key market events by our award-winning B2B team.

For more information on how you can be part of 'Manufacturing Chemist Stand Side' contact Don Phares on +44 207 193 3219 or via email: don@hpcimedia.com.

Featured companies

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life...
See more

You may also like

Manufacturing

Piramal Pharma Solutions commemorates opening of its ADC manufacturing expansion in Grangemouth, Scotland

Read more
Ribbon cutting and commissioning of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approximately 70-80%

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. Tabletability, compactability and compressibility: What’s the difference? To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be complicated. Here, the tablet experts Natoli explain how to develop tabletability, compactibility, and compressibility profiles
  3. TurboFil develops automatic assembly and vial-filling system for nasal devices The UDS Vial Filling & Assembly System can produce up to 100 nasal spray devices per minute
  4. Hubble Therapeutics selects Andelyn Biosciences to manufacture its AAVs The CDMO will be responsible for the manufacture of adeno-associated viruses in order to treat leber congenital amaurosis 16
  5. CDMO Kindeva Drug Delivery completes first vial batch at Bridgeton facility The CDMO plans to install four injectable fill-finish lines at the Bridgeton site, enhancing its annual production capacity to more than 100m units

Relevant companies

See more

Upcoming event

Lab Innovations

30-31 October 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Piramal Pharma Solutions commemorates opening of its ADC manufacturing expansion in Grangemouth, Scotland

Ribbon cutting and commissioning of a multipurpose state-of-the-art Antibody-Drug Conjugate (ADC) manufacturing facility that expands capacity by approximately 70-80%
Manufacturing

Piramal Pharma opens ADC manufacturing site in Grangemouth, Scotland

The commissioning of the facility represents the culmination of a £45m investment to address rapidly growing demand for ADC manufacturing, supported by a £2.4m Scottish Enterprise grant
Manufacturing

Piramal reveals financial results for fourth quarter

“Over the recent years, Q4 has always been the strongest quarter for the company in terms of revenue contribution and EBITDA margin"
Manufacturing

Piramal Pharma begins production of APIs in new reactor suites

New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
Manufacturing

Piramal Pharma Solutions announces winner of its 2022 Award for Excellence in Patient Centricity

The Excellence Award recognises the hands-on application of Patient Centricity and a focus on helping to reduce the burden of disease on patients
Manufacturing

Piramal Pharma enters the stockmarket with BSE and NSE

In June 2020, Piramal had signed an agreement with The Carlyle Group to invest growth equity capital for a 20% stake in its company
Manufacturing

Piramal expands API capabilities at Digwal and applies operational excellence tools to release capacity

Site has a capital investment programme of $30 million spent or committed during the last 3 years to expand capabilities and improve operational efficiencies
Subscribe now